Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - levodopa 200 mg; entacapone 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - solution for injection - treprostinil as sodium 5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - solution for injection - treprostinil as sodium 2.5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Israel - English - Ministry of Health

lundbeck israel ltd. - sertindole - film coated tablets - sertindole 4 mg - sertindole - sertindole - for the treatment of schizophrenia. due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.

Israel - English - Ministry of Health

lundbeck israel ltd. - sertindole - film coated tablets - sertindole 16 mg - sertindole - sertindole - for the treatment of schizophrenia. due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.